Related Experiment Videos
Neoadjuvant chemotherapy in operable breast cancer
S M Scholl1, B Asselain, T Palangie
1Department of Clinical Oncology, Institut Curie, Paris, France.
European Journal of Cancer (Oxford, England : 1990)
|January 1, 1991
Summary
Neoadjuvant chemotherapy, given before surgery for localized breast cancer, is safe and as effective as adjuvant chemotherapy. This approach may help prevent tumor spread and reduce micrometastasis proliferation.
Area of Science:
- Oncology
- Clinical Trials
- Breast Cancer Research
Background:
- Primary chemotherapy for localized breast cancer aims to prevent tumor spread during surgery.
- It may also reduce the proliferation of micrometastases.
Purpose of the Study:
- To compare neoadjuvant and adjuvant chemotherapy regimens in operable breast cancer patients.
- To evaluate the efficacy and safety of neoadjuvant chemotherapy prior to locoregional therapy.
Main Methods:
- A randomized clinical trial involving 196 pre- and postmenopausal patients with operable breast cancer (T2-3, N0-1b).
- Comparison of neoadjuvant (pre-surgery) versus adjuvant (post-surgery) chemotherapy regimens (doxorubicin/cyclophosphamide/5-fluorouracil).
- Patients received radiotherapy with or without surgery; follow-up ranged from 35-70 months (median 54).
Main Results:
- Tumor response after two cycles of neoadjuvant chemotherapy was significantly associated with dose (P = 0.003).
- Survival showed a slight, non-significant advantage for the neoadjuvant group.
- Neoadjuvant chemotherapy was found to be safe and at least as effective as the adjuvant regimen.
Conclusions:
- Neoadjuvant chemotherapy is a safe and effective treatment option for localized breast cancer.
- The findings support the use of chemotherapy as a first-line treatment in a subsequent larger trial.